M/s. Prince Pharma Depot Pharmaceti Pharmaceutical Import Profile — Congo Dr (DGFT 2022–2026)

Name: M/s. Prince Pharma Depot Pharmaceti Pharmaceutical Import Records from India — 2 Products, $700.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Prince Pharma Depot Pharmaceti — Pharmaceutical Importer Profile (2026) | 2 Products, $700.0K Trade | TransData Nexus

M/s. Prince Pharma Depot Pharmaceti

Pharmaceutical Importer · Congo Dr · Advanced Antibiotics Focus · $700.0K Total Trade · DGFT Verified

M/s. Prince Pharma Depot Pharmaceti is a pharmaceutical importer based in Congo Dr with a total trade value of $700.0K across 2 products in 1 therapeutic categories. Based on 14 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. Prince Pharma Depot Pharmaceti sources from 1 verified Indian supplier, with Sakar Healthcare Limited accounting for 100.0% of imports.

M/s. Prince Pharma Depot Pharmaceti — Import Portfolio & Supplier Network

M/s. Prince Pharma Depot Pharmaceti import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Prince Pharma Depot Pharmaceti?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sakar Healthcare Limited	$1.2M	56	100.0%

M/s. Prince Pharma Depot Pharmaceti sources from 1 verified Indian supplier across 27 distinct formulations. The sourcing is highly concentrated — Sakar Healthcare Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Cefixime tablets 200MG (cefiprin-200)	$151.6K	4
Cefotaxime for injection USP &	$146.6K	4
Magaldrate and simethicon oral	$135.3K	7
Combipack of ceftriaxone sodium and	$131.1K	3
Cefixime tablets 400MG (cefiprin-400)	$118.7K	3
Omeprazole for injection (omekar) (as	$116.6K	4
Pantoprazole for injection BP (pentokar)	$110.3K	4
Zinc sulfate tablets USP 20MG (zinc-dt)	$103.0K	3
Cefixime tablets USP 200MG	$50.0K	1
Cefpodoxime proxetil for oral	$32.2K	3
Amikacine injection BP 250MG/ML	$19.9K	2
Cefpodoxime proxetil dispersible	$16.6K	1
Cefiprin tablets USP 200MG	$16.3K	1
Potassium citrate,magnesium citrate	$9.7K	1
Potassium citrate, magnesium citrate	$9.1K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cefixime	Advanced Antibiotics	$550.0K	11	0.3%	2
2	Ceftriaxone	Advanced Antibiotics	$150.0K	3	0.1%	7

M/s. Prince Pharma Depot Pharmaceti imports 2 pharmaceutical products across 1 categories into Congo Dr totaling $700.0K.

M/s. Prince Pharma Depot Pharmaceti — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Prince Pharma Depot Pharmaceti is a prominent pharmaceutical importer and distributor based in the Democratic Republic of Congo (DRC). The company is headquartered at Avenue Luambo Makiadi No. 03, Commune De La/Gombe, Kinshasa, DRC. (princepharma.co) Established over a decade ago, Prince Pharma has positioned itself as a leading healthcare provider in the region, committed to delivering quality and affordable healthcare solutions across Central and East Africa. (princepharma.co)

The company specializes in the importation and distribution of a diverse range of pharmaceutical products, including both branded and generic medicines. These products span various therapeutic areas, ensuring comprehensive healthcare solutions for the Congolese population. Prince Pharma's offerings encompass over 600 prescription and over-the-counter brands across more than 16 therapeutic areas, reflecting its extensive portfolio. (princepharma.co) The company's mission is to make lives healthier by ensuring the availability of quality and affordable medicines for all. (princepharma.co)

2Distribution Network

Prince Pharma operates a modern, ISO 9001:2015-certified warehouse equipped with Warehouse Management System (WMS) software and an automated system that streamlines picking and optimizes inventory. This facility also forecasts demand, ensuring efficient operations and exceptional service. Additionally, the company maintains cold storage facilities that uphold controlled temperatures for perishable goods, featuring real-time temperature monitoring. These logistics capabilities enable Prince Pharma to effectively manage its distribution network, ensuring the timely and safe delivery of pharmaceutical products across the DRC. (princepharma.co)

3Industry Role

Prince Pharma Depot Pharmaceti plays a pivotal role in the DRC's pharmaceutical supply chain as a primary wholesaler and distributor. By importing a wide array of pharmaceutical products, the company ensures that both urban and remote areas have access to essential medicines. Its extensive distribution network and commitment to quality and affordability have solidified its position as a key player in the Congolese healthcare sector. (princepharma.co)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Prince Pharma Depot Pharmaceti

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Prince Pharma's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a single supplier, Sakar Healthcare Limited. This supplier has been responsible for 100% of the company's pharmaceutical imports from India, amounting to $1.2 million across 56 shipments. Such a concentrated sourcing approach can present risks, including potential supply chain disruptions if the primary supplier faces operational challenges. However, this strategy may also reflect a strategic choice aimed at maintaining consistent product quality and favorable pricing. The stability of the relationship with Sakar Healthcare Limited is crucial for Prince Pharma's operations, and any changes in this partnership could significantly impact the company's supply chain dynamics.

2Supply Chain Resilience

The resilience of Prince Pharma's supply chain is closely tied to its reliance on a single supplier for pharmaceutical imports from India. While this concentration can streamline procurement processes and strengthen supplier relationships, it also exposes the company to risks associated with supplier dependency. The absence of backup suppliers for Indian imports means that any disruptions at Sakar Healthcare Limited could lead to significant supply chain challenges. Additionally, the limited diversity in imported formulations, with only 27 unique formulations, may restrict the company's ability to adapt to changing market demands or regulatory requirements. To enhance supply chain resilience, Prince Pharma may consider diversifying its supplier base and expanding its product portfolio.

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Congo Dr

1Regulatory Authority & Framework

The Congolese Pharmaceutical Regulatory Authority (ACOREP) is the primary body responsible for regulating pharmaceutical imports and ensuring compliance with national health standards in the DRC. ACOREP oversees the authorization and control of drug imports and exports, ensuring that all pharmaceutical products meet the required safety and efficacy standards. The regulatory framework governing pharmaceutical imports includes obtaining an import license from an authorized commercial bank and undergoing a pre-shipment inspection by Bureau Veritas for shipments valued over $2,500. Additionally, a Certificate of Pharmaceutical Product (CPP) is a critical document for quality control, with initial screenings conducted locally and more comprehensive analyses performed at WHO-prequalified laboratories abroad.

2Import Licensing & GMP

Importers in the DRC are required to secure an import license from an authorized commercial bank before the physical shipment of goods. For pharmaceutical imports valued at $2,500 or more, a mandatory pre-shipment inspection by Bureau Veritas is required. While Good Manufacturing Practice (GMP) certification is officially required, enforcement is often inconsistent; a Certificate of Pharmaceutical Product (CPP) is a critical document. For quality control, initial screening is conducted locally using methods like the GPHF Minilab, with more comprehensive analysis performed at WHO-prequalified laboratories abroad.

M/s. Prince Pharma Depot Pharmaceti — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Prince Pharma's focus on importing advanced antibiotics, particularly cefixime and ceftriaxone, indicates a strategic alignment with the prevalent healthcare needs in the DRC. The high import values of these antibiotics suggest a significant demand for effective treatments against bacterial infections. This emphasis on advanced antibiotics may be driven by the need to address public health challenges related to infectious diseases in the region.

2Sourcing Profile

Prince Pharma's sourcing strategy is heavily concentrated on a single supplier, Sakar Healthcare Limited, for its pharmaceutical imports from India. This approach may be aimed at ensuring consistent product quality and favorable pricing. However, the limited diversity in suppliers and formulations could pose risks related to supply chain disruptions and adaptability to changing market demands.

3Market Positioning

Based on its product mix, Prince Pharma primarily serves the wholesale distribution segment of the DRC market. By importing and distributing a range of pharmaceutical products, the company ensures that both urban and remote areas have access to essential medicines, thereby playing a crucial role in the country's healthcare supply chain.

Seller's Guide — How to Become a Supplier to M/s. Prince Pharma Depot Pharmaceti

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the DRC market by offering complementary products or services that align with Prince Pharma's needs. While the existing relationship between Prince Pharma and Sakar Healthcare Limited presents challenges, new suppliers can explore niches or unmet needs within the market to establish partnerships. Diversifying the supplier base could enhance supply chain resilience and adaptability to changing market conditions.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Prince Pharma and the DRC market must obtain an import license from an authorized commercial bank in the DRC. They must also ensure that their products comply with the DRC's quality control measures, including obtaining a Certificate of Pharmaceutical Product (CPP) and undergoing pre-shipment inspections as required. Additionally, all documentation and labeling must be in French to meet regulatory standards.

3How to Approach

Frequently Asked Questions — M/s. Prince Pharma Depot Pharmaceti

What products does M/s. Prince Pharma Depot Pharmaceti import from India?

M/s. Prince Pharma Depot Pharmaceti imports 2 pharmaceutical products across 1 categories. Top imports: Cefixime ($550.0K), Ceftriaxone ($150.0K).

Who supplies pharmaceuticals to M/s. Prince Pharma Depot Pharmaceti from India?

M/s. Prince Pharma Depot Pharmaceti sources from 1 verified Indian suppliers. The primary supplier is Sakar Healthcare Limited (100.0% of imports, $1.2M).

What is M/s. Prince Pharma Depot Pharmaceti's total pharmaceutical import value?

M/s. Prince Pharma Depot Pharmaceti's total pharmaceutical import value from India is $700.0K, based on 14 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Prince Pharma Depot Pharmaceti focus on?

M/s. Prince Pharma Depot Pharmaceti imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full M/s. Prince Pharma Depot Pharmaceti Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.